No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

Show other versions (1)

The aim of this study was to test the effects of the KIF6 Trp719Arg polymorphism (rs20455) on vascular risk and response to statin therapy in 18,348 participants from the Heart Protection Study.

Bibliographic Details
Main Authors:	Hopewell, J, Parish, S, Clarke, R, Armitage, J, Bowman, L, Hager, J, Lathrop, M, Collins, R, MRC/BHF Heart Protection Study Collaborative Group
Format:	Journal article
Language:	English
Published:	2011

Similar Items

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
by: Hopewell, J, et al.
Published: (2009)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
by: Heart Protection Study Collaborative Group
Published: (2007)

Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
by: Heart Protection Study Collaborative Group
Published: (2010)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
by: Emberson, JR, et al.
Published: (2007)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
by: Heart Protection Study Collaborative Group
Published: (2002)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
by: Hopewell, J, et al.
Published: (2011)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
by: Link, E, et al.
Published: (2008)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2011)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
by: Mihaylova, B, et al.
Published: (2009)

Cardiovascular outcomes among participants with diabetes in the recent large statin trials.
by: Armitage, J, et al.
Published: (2004)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
by: Hopewell, J, et al.
Published: (2014)

The safety of statins in clinical practice.
by: Armitage, J
Published: (2007)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
by: Mangravite, L, et al.
Published: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
by: Mangravite, L, et al.
Published: (2013)

Misrepresentation of statin safety evidence.
by: Armitage, J, et al.
Published: (2014)

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials
by: Offer, A, et al.
Published: (2019)

The regulation of KIF3A motor subunit by phosphorylation
by: Chen, Kunning
Published: (2018)

Characterisation of mitotic phosphorylation on chromokinesin KIF4A
by: Ang, Anthony Wei Tzerl
Published: (2015)

Safety and efficacy of statins - Authors' reply
by: Collins, R, et al.
Published: (2017)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)

Lessons from the controversy over statins - Authors' reply.
by: Armitage, J, et al.
Published: (2016)

AMW 348 - PERUNCITAN MAC 05.
by: PPP, Pusat Pengajian Pengurusan
Published: (2005)

JTP 348 - PERUNCITAN MAC 05.
by: PPJJ, Pusat Pengajian Jarak Jauh
Published: (2005)

AMW348 – PERUNCITAN MAC 05.
by: PPP, Pusat Pengajian Pengurusan
Published: (2005)

The regulation of KIF3 motor complex by POPX2 phosphatase
by: Phang, Hui Qun
Published: (2012)

Does the benefit from statin therapy extend beyond 5 years?
by: Bulbulia, R, et al.
Published: (2013)

Does the benefit from statin therapy extend beyond 5 years?
by: Bulbulia, R, et al.
Published: (2013)

Prescribing statins.
by: Aronson, J
Published: (2005)

KIF1B, the First Neuronally Expressed Gene Associated with Multiple Sclerosis
by: Hoppenbrouwers, I, et al.
Published: (2009)

Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis.
by: Aulchenko, Y, et al.
Published: (2008)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
by: Hopewell, J, et al.
Published: (2010)

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
by: Haynes, R, et al.
Published: (2019)

Dementia and statins.
by: Ebrahim, S, et al.
Published: (2001)

JTP 348 - PERUNCITAN FEB-MAC 03.
by: PPJJ, Pusat Pengajian Jarak Jauh
Published: (2003)

AMP 348 ï¿½ PERUNCITAN FEB 01.
by: PPP, Pusat Pengajian Pengurusan
Published: (2001)

AMP 348 ï¿½ RETAILING FEB 01.
by: PPP, Pusat Pengajian Pengurusan
Published: (2001)

AMP 348 - Retailing - February - March 2001
by: PPP, Pusat Pengajian Pengurusan
Published: (2001)

POPX2 phosphatase regulates the KIF3 kinesin motor complex
by: Phang, Hui-Qun, et al.
Published: (2015)

KIF14 and citron kinase act together to promote efficient cytokinesis.
by: Gruneberg, U, et al.
Published: (2006)